Is this RTRX news suppose to be bad news for IPCI? You are a short-term technical trader. Why are you reading news? Anyway, I suppose you think oxytocin is a pain killer.
How about Enterprise Value (Dec 18, 2013) $83.01M? What is that used for?
Seekingalpha FAKE headline makes it sound like DARA just got Orphan Designation. Headline should be "Orphan Designation WOULD BE a game changer for DARA" using future-tense.
"what a maroon" Maroon is a dark brownish-red color. Or do you mean id-ee-ut or more-on. Or does Yahoo filter moron, moron, moron, moron.
Mitch, what do you think of Soltamox revenue in latest quarter? Did not you say I would get a spanking when September 2013 quarter earnings came out? I think company did not break-down revenue by product in press releases, but Zacks analyst got it out of them. I think he said Soltamox had around $50,000 revenue while Gelclair was $70,000 revenue. So Gelclair outsold Soltamox. Also, Soltamox revenue actually lower than launch quarter. Does not Soltamox have $20-$25 million peak sales project by 2018 by Zacks analyst? Is DARA too embarrassed to reveal the number of prescriptions for Soltamox?
Anyway, maybe company will have better luck with the new three products from Mission Pharmacal. How come the longs on DARA board do not talk about them? Do they even know what they are? I would give the iron supplement the best chance, the other two look like duds to me.
BUY BUY IPCI. Good recommendation Gregory. Anyway, good to see you back as you disappeared for a couple of weeks.
Sentiment: Strong Buy
IPCI is a generic drug pharmaceutical. It is not a biotech. It is not new-drug pharmaceutical. So it is a boring generic drug company like Lannett, Hi-Tech Pharmacal, Mylan, Actavis (Watson), Impax, and Teva. If IPCI gets to break-even with generic Focalin, I would hold and accumulate IPCI for the next 5 to 10 years and watch it grow to a billion dollar company.
OK, I see a message about update to New Economy Portfolio in the message section with DARA. But in the above listing of trades for the New Economy Portfolio, I only see up to 11/6/2013 followed by empty space between that and the Beginner Portfolio.
Paladin Labs sells mostly branded drugs in Canada, so maybe not a good idea to partner with them.
How about getting approval in Canada? IPCI is in Canada. Maybe IPCI could partner with a Canadian company like Apotex or Paladin Labs to get their generic drugs approved in Canada.
How fast does he update the website? Portfolio on top seems to have no open positions. Beginner portfolio at the bottom has open positions on 11/29/13 ACHN $3.24, 12/2/13 CPRX $1.80, and 12/4/13 CYTR $2.6. He does email about his personal trades, which are not portfolio trades. So is DARA one of Sheff's personal trades?
Is Sheff back in just rumor? Only thing I see at investorshub is someone asking Sheff what he thought about DARA. And Sheff replied, "It looks good". I do not see DARA in the two portfolios either.
fab_you_licious_five wrote: "found DSNY and made a 30% return" Pete wrote about DSNY about 2 weeks before earnings 11/25/2013. He was probably expecting spectacular earnings due to new licenses. I think revenues were slightly down and earnings were slightly down. So it was luck that it went up a few days after earnings.
Holywallst wrote:"have seen bio stocks do that." IPCI is not a bio. It is a pharma. It develops mostly generics. Even the name contains the word pharma. You must be dense to keep calling it a biotech and comparing it to biotech stocks.
Sentiment: Strong Buy
Holywallst, have you figured out that IPCI is a pharmaceutical and not a biotech. Or do you just post nonsense to put doubt into peoples heads. A one drug development stage biotech can plunge or go through the roof on FDA decisions. Also these are FDA ANDA filings for generics not NDAs for new drugs. These ANDAs will take years to get approved. Since obviously you have a short term view, why do you comment about FDA rejection every time someone points out the 7 ANDAs and more ANDAs to come.
HOLYWALLST, IPCI is a pharmaceutical not a biotech. Pharmaceuticals deal with chemicals while biotechs deal with biological stuff. So you are mistaken lumping IPCI with risky development stage biotechs. Lump IPCI with initial commercial stage generic drug companies.
So you think you can predict short-term fluctuations of IPCI? Then you will make lots of money trading. Go ahead.
IPCI options are held by employees and executive officers and are issued by the company stock options plan. Hope employees are strong stock holders with long-term view.
IPCI options are also in the money, in addition to warrants. Roughly $23 million of existing dilution. Someone pointed out the Oct 2013 presentation on website listed existing warrants and options. It says there are warrants with an average price $2.46 for 2.8M shares and options with an average price of $3.95 for 4.5M shares. Warrants would raise roughly $6 million and options would raise roughly $17 million. Outstanding shares would rise from 21 million to 28 million.
Anyway, hope many exercise their IPCI warrants and options. Early investors deserve to be rewarded and company needs capital. So there probably is no need for any new dilution if IPCI share price stays above $3 for the warrants and above $4 for the options.
Watson approved for 30mg on 11/21/2013. Teva got approved for 5mg, 10mg, 20mg, 40mg on 11/19/2013. IPCI got approved for 15mg and 30mg on 11/18/2013.
Teva generic website said they launched 40mg. Mylan got approved for 30mg a few months ago, 8/28/2013, but only announced launch last week. So news about others also getting approved probably put pressure on IPCI stock after the initial rally on Monday. Of course, I am referring to ANDA's for Dexmethylphenidate HCL or generic Focalin.
Some analyst wrote IPCI and TEVA agreed to 180 day co-exclusive launch for lower doses. Is that true or false? I have not found anything about that on IPCI website or filings. At this time, IPCI only has FDA tentative approval on lower doses, 5mg, 10mg, and 20mg, probably because TEVA filed first and has been assigned the 180 day exclusivity.